Lupin gains as its arm gets USFDA’s nod for supplemental new drug application for SOLOSEC

02 Jul 2021 Evaluate

Lupin is currently trading at Rs. 1155.15, up by 8.90 points or 0.78% from its previous closing of Rs. 1146.25 on the BSE.

The scrip opened at Rs. 1154.80 and has touched a high and low of Rs. 1166.90 and Rs. 1151.70 respectively. So far 25796 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 828.65 on 27-Jul-2020.

Last one week high and low of the scrip stood at Rs. 1172.45 and Rs. 1140.00 respectively. The current market cap of the company is Rs. 52893.29 crore.

The promoters holding in the company stood at 46.86%, while Institutions and Non-Institutions held 40.46% and 12.69% respectively.

Lupin’s U.S. based wholly-owned subsidiary -- Lupin Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration (USFDA) for its supplemental New Drug Application (sNDA) to expand the use of SOLOSEC (secnidazole) to include the treatment of trichomoniasis in adults.

Trichomoniasis vaginalis is the most common non-viral, curable sexually transmitted infection (STI) in the U.S., affecting an estimated three to five million people every year. SOLOSEC was approved in the U.S. in 2017 for the treatment of bacterial vaginosis (BV) in adult women. The supplemental approval makes SOLOSEC the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2131.80 10.15 (0.48%)
29-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1589.30
Dr. Reddys Lab 1208.45
Cipla 1320.35
Zydus Lifesciences 890.20
Lupin 2131.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×